First Financial Bank Trust Division Sells 612 Shares of Bristol-Myers Squibb (NYSE:BMY)

First Financial Bank Trust Division trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,689 shares of the biopharmaceutical company’s stock after selling 612 shares during the quarter. First Financial Bank Trust Division’s holdings in Bristol-Myers Squibb were worth $688,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Financial Engines Advisors L.L.C. acquired a new stake in Bristol-Myers Squibb in the third quarter worth $241,000. Rafferty Asset Management LLC grew its holdings in Bristol-Myers Squibb by 7.6% in the third quarter. Rafferty Asset Management LLC now owns 224,040 shares of the biopharmaceutical company’s stock worth $13,003,000 after purchasing an additional 15,770 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new stake in Bristol-Myers Squibb in the third quarter worth $4,499,000. Grantham Mayo Van Otterloo & Co. LLC grew its holdings in Bristol-Myers Squibb by 2.7% in the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 643,084 shares of the biopharmaceutical company’s stock worth $37,325,000 after purchasing an additional 16,953 shares during the period. Finally, Sargent Investment Group LLC grew its holdings in Bristol-Myers Squibb by 5.6% in the third quarter. Sargent Investment Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $567,000 after purchasing an additional 521 shares during the period. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on BMY shares. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Barclays reduced their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Finally, BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Price Performance

NYSE:BMY traded down $0.67 during mid-day trading on Tuesday, hitting $40.30. 6,679,943 shares of the stock traded hands, compared to its average volume of 15,377,682. The business’s 50-day moving average price is $44.30 and its 200 day moving average price is $48.67. The company has a market cap of $81.69 billion, a PE ratio of -13.16, a price-to-earnings-growth ratio of 13.95 and a beta of 0.43. Bristol-Myers Squibb has a 12-month low of $39.91 and a 12-month high of $66.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.05 earnings per share. On average, analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.96%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.